Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Rituximab in Untreated FL and SLL
NCT02258529Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in follicular lymphoma (FL) and small lymphocytic lymphoma (SLL), sponsored by Gilead Sciences. Primary endpoint: Overall Response Rate. Started Sep 2015; status: terminated.
02
Drugs
idelalisib
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02258529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258529.